Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Shashi A. Gujar; Derek Clements; Patrick W.K. Lee

doi:10.4161/onci.27622

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Shashi A. Gujar, Derek Clements, Patrick W.K. Lee

Medicine

Medicine

Résultat de recherche: Article › examen par les pairs

18 Citations (Scopus)

Résumé

Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.

Langue d'origine	English
Numéro d'article	e27622
Journal	OncoImmunology
Volume	3
Numéro de publication	1
DOI	https://doi.org/10.4161/onci.27622
Statut de publication	Published - 2014

Note bibliographique

Funding Information:
This work was supported by the research grants from the Canadian Institute of Health Research (CIHR), Terry Fox Research

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.4161/onci.27622

Autres fichiers et liens

Citer

@article{9b750e36c2404c16a33316ad4b35931d,

title = "Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses",

abstract = "Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.",

author = "Gujar, {Shashi A.} and Derek Clements and Lee, {Patrick W.K.}",

note = "Funding Information: This work was supported by the research grants from the Canadian Institute of Health Research (CIHR), Terry Fox Research",

year = "2014",

doi = "10.4161/onci.27622",

language = "English",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Two is better than one

T2 - Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

AU - Gujar, Shashi A.

AU - Clements, Derek

AU - Lee, Patrick W.K.

N1 - Funding Information: This work was supported by the research grants from the Canadian Institute of Health Research (CIHR), Terry Fox Research

PY - 2014

Y1 - 2014

N2 - Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.

AB - Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.

UR - http://www.scopus.com/inward/record.url?scp=84899075616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899075616&partnerID=8YFLogxK

U2 - 10.4161/onci.27622

DO - 10.4161/onci.27622

M3 - Article

AN - SCOPUS:84899075616

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e27622

ER -

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer